MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Oct 12, 2023

Keywords

ClinConnect Summary

The MARINER Trial is studying a new way to monitor heart transplant patients for a condition called cardiac allograft vasculopathy (CAV), which happens when the blood vessels in the transplanted heart become narrow and can lead to problems with how the heart functions. This trial aims to find out if a noninvasive imaging technique called positron emission tomography (PET) is just as effective as the traditional method known as coronary angiography, which is a more invasive procedure that involves threading a catheter through the blood vessels.

To participate in this trial, you need to be at least 18 years old and have had a heart transplant between 2 to 10 years ago. You should also be able to give informed consent, meaning you understand what the trial involves. However, certain health conditions may prevent you from joining, such as severe heart issues or allergies to specific contrast dyes used in imaging. If you participate, you'll undergo the PET scan and may be closely monitored to see how well this method works for checking your heart's health compared to the standard procedure. This trial is currently recruiting participants, and it offers a chance to help improve care for future heart transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Post heart transplant 2-10 years.
• • 2. Age ≥18 years.
• • 3. Able to provide informed consent.
• Exclusion Criteria:
• • 1. Contraindication to dipyridamole due to severe aortic stenosis.
• • 2. Contraindication to dipyridamole due to 2:1 or greater AV block without pacemaker.
• • 3. Contraindication to dipyridamole due to severe bronchospasm.
• • 4. Unable to undergo coronary angiography due to allergy to iodinated contrast.
• • 5. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL/min/1.73 m2. for non-dialysis patients as determined by local laboratory analysis.
• • 6. Unable to undergo coronary angiography due to unsuitable vascular access.
• • 7. Treated rejection ≤1-month.
• • 8. Unstable angina or MI ≤7 days.